Table 1 Risk factors for CSC.

From: Treatment of central serous chorioretinopathy: new options for an old disease

Category

Risk factors

Key considerations

Corticosteroid use

Systemic corticosteroid use (oral, intravenous), local corticosteroid administration (inhaled, intranasal, epidural, intra-articular, topical, periocular) [19]

Steroid-induced CSC shows frequent bilaterality, atypical presentation and less male predilection than non-steroid-induced CSC [19]

Endogenous hormonal changes

Endogenous hypercortisolism (Cushing syndrome, adrenal/pituitary tumours, ectopic adrenocorticotropic hormone-secreting tumours) [4]; pregnancy-related hormonal changes (elevated cortisol, progesterone, testosterone) [22], renin–angiotensin system activation, increased blood volume [4]

CSC is the leading cause of pregnancy-related acquired retinal/choroidal visual impairment [22]

Autonomic dysfunction and sleep disorders

Sympathetic overactivation [23], decreased parasympathetic activity [98], obstructive sleep apnoea (5× increased risk) [23]

Association between CSC and autonomic imbalance [23]; sleep apnoea screening is recommended in patients with CSC [99]

Infectious and drug-related factors

Helicobacter pylori infection, sympathomimetic agents (pseudoephedrine, oxymetazoline), MMDA [25], phosphodiesterase-5 inhibitors (sildenafil, tadalafil) [26]

Pathophysiological mechanisms of H. pylori in CSC remain unclear [24]; drug-induced CSC should be considered in at-risk patients [3, 36]

Psychological and personality factors

Psychological stress, Type A personality [23], antipsychotic medication use, depression, adjustment disorder [28]

Recent studies using validated questionnaires found no clear association between CSC and maladaptive personality traits [29]

Genetic risk factors

Single-nucleotide polymorphisms in CFH (rs3753394, rs1329428, rs800292) [30, 31], VIPR2 (rs3793217) [32], CDH5 [4], TNFRSF10A-LOC389641, GATA5 [33]

Genetic variations may influence choroidal circulation and steroid response, but functional impacts require further research [31]

  1. CFH complement factor H, CSC central serous chorioretinopathy, MMDA 3-methoxy-4,5-methylenedioxyamphetamine.